[vc_row][vc_column][vc_empty_space height=”24″]
An estimated 18 to 32 per cent of patients with an ILD will have their condition evolve to a progressive fibrosing-ILD (PF-ILD), leading to respiratory failure and death within three to five years from diagnosis. Regular monitoring is important for the early detection of patients with a progressive course of the disease.<\/p>\n
\u201cAt the Firestone Institute for Respiratory Health, we\u2019re excited for the launch of CONNECT-ILD as it approaches ILD care holistically and goes beyond managing physical symptoms,\u201d says Dr. Martin Kolb, a respirologist at St. Joseph\u2019s Healthcare Hamilton, Director of the Respirology Division at McMaster University, and Canada\u2019s first research chair holder in interstitial lung disease. \u201cBy partnering to optimize care in an innovative, first-of-its-kind way, we are leveraging our strengths to collectively create sustainable and transformative healthcare solutions for patients.\u201d[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row_content” full_height=”yes” parallax=”true” parallax_image=”1617″][vc_column][vc_empty_space height=”750″][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css_animation=”slideInRight” css=”.vc_custom_1695247801419{background-color: #ffffff !important;}”]<\/p>\n
Clinicians at St. Joe’s Firestone Institute for Respiratory Health are piloting the CONNECT-ILD platform to improve the patient experience.<\/em><\/strong><\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_column_text]The collaboration uses the digital care journey platform\u2014SeamlessMD\u2014which was selected through a rigorous process from among 20 proposed solutions. The platform provides \u00a0patients with reminders, evidence-based education, progress tracking, symptom management, and allows for remote patient monitoring for patients who are diagnosed with ILD. The platform, accessible via app and web, features both patient and physician portals. The goals of the program are continuous monitoring of patients at higher risk of poor outcomes, reduced waitlist by limiting the need for in-person visits, and improved experience for patients and physicians.<\/p>\n A significant portion of the funding for this project was provided by the Ontario Centre of Innovation (OCI), which helps Ontario innovators connect with the researchers, industry partners, and funding needed to commercialize the next generation of made-in-Ontario IP and solutions.[\/vc_column_text][\/vc_column][vc_column width=”1\/2″]